SAN DIEGO, June 05, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference. The fireside chat session is scheduled for Monday, June 9, in Miami, FL, ...

Portfolio prioritization focuses on novel-novel combination therapy of BBI-355 and BBI-825 and new development candidate, BBI-940, for novel kinesin program Operating runway extended into the first half of 2028, through expected proof-of-concept clinical readouts for each program Conference call and webcast to be held Tuesday, May 27 at 8:00 am ET SAN DIEGO, May 23, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to ...

Initial proof-of-concept data from the ongoing BBI-355 Phase 1/2 POTENTIATE trial in patients with oncogene-amplified cancers anticipated in the second half of 2025 Novel Kinesin program on track for mid-2025 development candidate nomination and IND filing in the first half of 2026 $138 million cash position provides operating runway into 2027 SAN DIEGO, May 09, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to del ...

Company Overview - Boundless Bio is a clinical-stage oncology company focused on developing therapies for patients with oncogene amplified cancers by targeting extrachromosomal DNA (ecDNA), which is implicated in 14 to 17% of cancer cases [3]. - The company is developing its first ecDNA-directed therapeutic candidate, BBI-355, an oral inhibitor of checkpoint kinase 1 (CHK1), currently in a Phase 1/2 clinical trial [3]. - Boundless Bio utilizes its Spyglass platform for additional programs that are in preclinical development and discovery [3]. Upcoming Events - Zachary Hornby, President and CEO of Boundless Bio, will participate in a fireside chat at Leerink's Global Healthcare Conference on March 12, 2025, at 11:20 a.m. ET in Miami, FL [2]. - A live and archived webcast of the session will be available on Boundless Bio's website under the "Events & Presentations" section [2].